• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » DREAM Challenge winners announced

DREAM Challenge winners announced

September 23, 2015
CenterWatch Staff

Winners have been announced for the Prostate Cancer DREAM Challenge, the first research challenge in prostate cancer to marry crowdsourcing with data sharing, paving a new way to tackle key research questions about metastatic castration-resistant prostate cancer (mCRPC), an advanced form of the disease with poor outcomes.

The challenge called upon the cancer research and computational biology community to find solutions to key open clinical research questions about mCRPC and explore innovative research and modeling approaches. The three specific questions posed were to:

  • Predict overall survival for prostate cancer patients using clinical data.
  • Predict the exact time to event for prostate cancer patients using clinical data.
  • Predict treatment discontinuation for prostate cancer patients treated with docetaxel.

The challenge produced unprecedented levels of participation, with more than 550 registrants, comprising more than 60 teams. Three rounds of leader-board scoring allowed teams to submit up to five predictions per round; in total, nearly 1,200 model predictions and almost 160 final submissions were received across two sub-challenges.

Best performers include Team FIMM-UTU from the University of Turku, Finland, and the University of Helsinki, Finland, for the first question regarding prediction of overall survival; and Yuanfang Guan from the University of Michigan for the second question regarding prediction of treatment discontinuation.

“The DREAM Challenge was rewarding in that it enabled us to participate in a collaborative project in which researchers from multiple institutes worked together and compared findings with other teams,” said Tero Aittokallio, a member of Team FIMM-UTU. “The most rewarding part, however, will be to see how our findings will eventually help patients with metastatic castrate resistant prostate cancer.”

Challenge winners and results can be found on the Prostate Cancer DREAM Challenge homepage. The winners will be invited to co-author a challenge overview paper that will be submitted for peer review to Nature Biotechnology. Winners also will each receive a share of an educational award from Project Data Sphere, sponsored by AstraZeneca. Solvers will be able to submit write-ups on their models to F1000Research, an open science publishing platform, where the models can be reviewed.

“More than 550 researchers from around the world accessed the data over the course of the challenge,” said Dr. James Costello, University of Colorado Anschutz Medical Campus. “Without the efforts from Project Data Sphere, Sage Bionetworks with the support and experience of the DREAM Challenges Initiative, and our clinical trial collaborators, these data would have been difficult to access and even harder to use. Project Data Sphere performed a great deal of data curation to make the clinical variates readily accessible.”

Data for the challenge was standardized and integrated from four different, de-identified clinical trials with more than 2,000 mCRPC patients treated with first-line docetaxel. The data sets were provided to Project Data Sphere by AstraZeneca, Celgene, Memorial Sloan-Kettering Cancer Center and Sanofi U.S.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing